author-photo

Christian Jacques

Celgene

79

Papers

6047

Citations

Citation Trend

Filter By

Papers (58) Sort By

Journal Conference Others

La face cachée de Facebook

2021
Show All
- Source
- Cite
- Save
Citations (0)
Pile ou face?: Ou lorsque nos croyances nous jouent des tours…

2021
Show All
- Source
- Cite
- Save
Citations (0)
Le recrutement dans la recherche sur le jeu avec des mises d'argent personnel

2020
Show All
- Source
- Cite
- Save
Citations (0)
ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR: PF608

2019
Show All
- Source
- Cite
- Save
Citations (1)
Abstract CT080: Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)

2019 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan

2017 Journal of The Formosan Medical Association
Show All
- Source
- Cite
- Save
Citations (2)
MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)